97 Results
Sort By:
Published on August 2, 2019
Researchers and patients from Austin Health and the University of Melbourne have taken part in the largest ever study looking at the genetic sequences of people with epilepsy. The findings (“Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals”), published in the American Journal of Human…
Published on February 11, 2019
The Epilepsy Society, a U.K.-based nonprofit, and UCB, will partner to develop personalized treatments for epilepsy through a partnership launched today with €2.5 million ($2.8 million) from the Belgian biotech. UCB’s contribution will go toward a five-year genomics research program designed to develop an improved and deeper understanding of the…
Published on December 11, 2018
An international team of researchers, including scientists at the Royal College of Surgeons in Ireland (RCSI), has discovered 11 new genes associated with epilepsy. The study (“Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies”), published in Nature Communications, greatly advances knowledge of the underlying…
Published on November 19, 2018
A drug previously approved for treating migraine and epilepsy has been found to slow the growth of triple negative breast cancer in mouse models. Researchers in the U.S., Taiwan, and China carried out screening studies to identify known pharmacologically active compounds that trigger degradation of N-Ras, a key protein that…
Published on August 7, 2018
Boston Children’s Hospital said today it plans to sequence the DNA of 3,000 patients with epilepsy or inflammatory bowel disease and their family members, in what it called a strategic initiative to expand its research genomics gateway. Patients with epilepsy or inflammatory bowel disease of likely genetic origin, undiagnosed after…
Published on December 5, 2016
Neurologic disorders diagnostics company Evogen, and biopharmaceutical company UCB announced today a collaboration to further develop and refine EvoScore START, Evogen’s new proteomic blood test that has been designed to more accurately distinguish epileptic seizures from other similar medical events. It is estimated that only 15% of suspected seizure-like events…
Published on May 15, 2024
An electron microscopy-based reconstruction of a cubic millimeter of cortex has been generated by Google’s Connectomics team and Harvard researchers. The 3D map, from a patient with epilepsy, extends through all cortical layers, is the volume of about one-millionth of a whole brain—smaller than a grain of rice. It contains…
Published on April 1, 2024
The adult human brain is made up of billions of neurons and glial cells. Understanding the diversity of these cells and their distinctive gene-regulatory mechanisms is crucial for determining how the brain works and, in turn, for developing treatments for neurologic disorders. Until recently, cell populations were defined based on…
Published on April 1, 2024
By Frieda Wiley Treating chronic illnesses usually saves lives. However, when that condition lacks a billing code, seeking treatment can become a death sentence. At least that’s what doctors told Amber Freed, a 43-year-old mother of two who learned that something seemingly as trivial as a billing code could become…
Published on February 21, 2024
A tiny light-triggered device that is thinner than a human hair can be used to control electrical activity in the body like cardiac pacemakers, according to research from the University of Chicago. The research, published in Nature, is still at an early stage, but the team behind the technology think…
Published on December 20, 2023
Life is like the changing of seasons, each uniquely beautiful. Just as autumn leaves fall to the ground and make way for winter’s gentle snow, life has transformational cycles. The cycle of life continues through the changing seasons, like how the autumn winds strip the trees of their leaves and…
Published on December 7, 2023
AbbVie is acquiring Cerevel Therapeutics and its neuroscience portfolio of multiple clinical-stage and preclinical candidates for $8.7B. Cerevel’s pipeline addresses diseases including schizophrenia, Parkinson’s disease (PD), and mood disorders. Its lead candidates are emraclidine for schizophrenia (Phase II) and psychosis (Phase I), and tavapadon in Phase III for PD. AbbVie…
Published on December 1, 2023
A study led by researchers at University College London (UCL) reveals that slow waves, typically associated with the brain’s sleep state, can also occur during wakefulness in individuals with epilepsy. These wakeful slow waves appear to act as a natural protective mechanism against the heightened brain excitability linked to epileptic…
Published on July 27, 2023
A multidisciplinary team at UC San Diego Health, participating in a clinical trial sponsored by Neurona Therapeutics, recently injected regenerative brains cells into the brain of a patient in an effort to treat their epileptic seizures. The regenerative brain cell therapy uses interneurons derived from human stems cells and has…
Published on May 17, 2023
Looking to deepen its services to the pharmaceutical and biotech industry, Google Cloud announced Tuesday at Bio-IT World Conference in Boston, the debut of two AI-powered research suites—one for target and lead identification and another multiomics. The Target and Lead Identification Suite will help researchers understand the function of amino…